Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE) and Unicycive Therapeutics (UNCY).
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Pfizer (PFE)
In a report issued on June 23, Asad Haider from Goldman Sachs maintained a Hold rating on Pfizer, with a price target of $26.00. The company’s shares closed last Friday at $24.12.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Pfizer with a $28.83 average price target, representing a 21.4% upside. In a report issued on June 9, RBC Capital also upgraded the stock to Hold with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Unicycive Therapeutics (UNCY)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, with a price target of $22.00. The company’s shares closed last Friday at $7.05.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unicycive Therapeutics with a $41.50 average price target.
Read More on PFE:
Disclaimer & DisclosureReport an Issue
- Pfizer Halts Tafamidis Bioequivalence Study: What It Means for PFE Investors
- Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer
- Pfizer Advances New Pediatric Pneumococcal “Catch-Up” Vaccine in Phase 3 Trial
- FDA approves Pfizer’s Ibrance combo for metastatic breast cancer
- Nike Stock (NKE) Rises on CFO Change, but Evercore Analyst Warns of Transition Risks
